Skip to main content
Lytix Biopharma AS logo

Lytix Biopharma AS — Investor Relations & Filings

Ticker · LYTIX ISIN · NO0010405780 LEI · 549300NXMIMRSBCDZO71 OL Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2024-08-23 Report Publication Anno…
Country NO Norway
Listing OL LYTIX

About Lytix Biopharma AS

https://www.lytixbiopharma.com/

Lytix Biopharma AS is a clinical-stage immuno-oncology company that develops a proprietary platform of oncolytic molecules for cancer treatment. The company's technology is based on molecules designed to selectively target and lyse cancer cell membranes. This process releases a broad spectrum of tumor antigens, which in turn stimulates a patient's immune system to recognize and attack the cancer, effectively turning immunologically "cold" tumors "hot". Its lead drug candidate, ruxotemitide, is being evaluated in clinical trials as a neoadjuvant treatment for various solid tumors, including melanoma and basal cell carcinoma.

Recent filings

Filing Released Lang Actions
Lytix Biopharma: Invitation to Q2 2024 Results Presentation
Report Publication Announcement Classification · 98% confidence The document is titled 'Lytix Biopharma: Invitation to Q2 2024 Results Presentation' and explicitly invites recipients to a live webcast presentation to discuss the second quarter 2024 financial results scheduled for August 29, 2024. This is not the full financial report (IR) itself, nor is it the initial key highlights announcement (ER). Instead, it is an announcement about the upcoming presentation of those results, including logistics for attending the call/webcast. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports/presentations.
2024-08-23 English
Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones
Investor Presentation Classification · 99% confidence The document is explicitly titled 'First quarter 2024 presentation' and contains slides detailing clinical progress, product candidates, market potential, and key financial figures for Q1 2024 (e.g., 'Key figures – profit and loss' table comparing Q1 2024 to Q1 2023). This structure—a presentation summarizing quarterly performance and operational updates—is characteristic of an Investor Presentation (IP). It is not a full regulatory report (like 10-K or IR), nor is it merely an announcement of a report (RPA).
2024-05-30 English
Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones
Earnings Release Classification · 100% confidence The document explicitly states it is releasing the 'first quarter 2024 results' and provides key financial highlights (revenue, fundraising) and clinical progress updates for that period. This structure—a summary of period results, key operational highlights, and financial figures for a specific quarter—is characteristic of an Earnings Release (ER). Although it mentions a webcast presentation will follow, the document itself is the initial announcement of the results, not just the announcement of the report's publication (RPA) or the full transcript (CT). It is too brief and focused on highlights to be a full Interim Report (IR). Q1 2024
2024-05-30 English
Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones
Earnings Release Classification · 100% confidence The document explicitly states, 'Lytix Biopharma... today releases its first quarter 2024 results.' It provides key financial highlights (revenue, fundraising) and operational updates (clinical trial progress) for the Q1 2024 period. This structure is characteristic of an Earnings Release (ER), which is the initial announcement of periodical financial results, focusing on key highlights rather than the comprehensive details found in a full Interim Report (IR). The document also mentions a webcast presentation, further supporting its nature as an initial results announcement. Q1 2024
2024-05-30 English
Lytix Biopharma: Invitation to presentation of first quarter 2024 results, Thursday 30 May 2024
Report Publication Announcement Classification · 98% confidence The document is very short (1539 characters) and explicitly serves as an 'Invitation to presentation of first quarter 2024 results'. It announces *when* the results will be released and *when* the presentation/webcast will occur, encouraging registration and question submission. It does not contain the actual financial results or the full report. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement about the publication or presentation of a report points towards a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since this specifically announces the release and presentation of quarterly results, RPA is the most fitting category, as it signals the upcoming availability of the actual financial report (which would likely be classified as IR if provided).
2024-05-22 English
Lytix Biopharma – Minutes of Ordinary General Meeting
AGM Information Classification · 100% confidence The document is explicitly titled 'PROTOKOLL FRA ORDINÆR GENERALFORSAMLING' (MINUTES FROM ANNUAL GENERAL MEETING) in both Norwegian and English. It details the proceedings, resolutions passed (approval of accounts, dividend distribution, board authorizations, election of directors/committees, and remuneration), and the date of the meeting (May 14, 2024). This content perfectly matches the definition of materials shared during an Annual General Meeting.
2024-05-14 Norwegian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.